SCHEMBL7248447

SCHEMBL7248447

CN(CC(=O)c1ccc2c(c1)OCCO2)C1C2CCC1CN(CCOc1ccc(C#N)cc1)C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
USP2 O75604 2/20 0.45
CTNNB1 P35222 2/20 0.41
LMNA P02545 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 1/20 0.41
CTSZ Q9UBR2 1/20 0.40
VNN1 O95497 1/20 0.39
HRH2 P25021 3/20 0.39
HRH1 P35367 3/20 0.39
KDM2B Q8NHM5 1/20 0.39
ALDH1A1 P00352 3/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
KDM4E B2RXH2 2/20 0.38
KCNA5 P22460 1/20 0.38
HTT P42858 1/20 0.38
WNT3A P56704 1/20 0.38
UTS2R Q9UKP6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7246200 0.88 KCNH2 (0.44) MAPTUSP2LMNASMN1; SMN2KMT2A
SCHEMBL7251183 0.85 NPC1 (0.42) MAPTUSP2LMNASMN1; SMN2TSHR
SCHEMBL7245234 0.85 ALDH1A1 (0.43) MAPTUSP2LMNASMN1; SMN2KMT2A
SCHEMBL2966034 0.80 MAPT (0.48) MAPTUSP2CTNNB1LMNASMN1; SMN2
SCHEMBL7250291 0.79 HRH2 (0.43) MAPTHRH2HRH1ALDH1A1KCNA5
SCHEMBL5965677 0.77 MAPT (0.46) MAPTUSP2CTNNB1LMNASMN1; SMN2
SCHEMBL7249141 0.76 KCNA5 (0.44) HRH2HRH1KCNA5HRH3
SCHEMBL2967585 0.76 KCNH2 (0.49) MAPTUSP2CTNNB1LMNASMN1; SMN2
SCHEMBL7252155 0.75 KCNA5 (0.48) SMN1; SMN2HRH2HRH1KDM4EKCNA5
SCHEMBL7245291 0.74 HRH3 (0.48) HRH2HRH1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6559162-B2 Electrophysiological activity ASTRAZENECA AB (SE) 2003-05-06 US disclosed
EP-1244631-A1 NEW AZABICYCLOOCTANE DERIVATIVES USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2002-10-02 EP disclosed
US-20020137766-A1 Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2002-09-26 US disclosed
WO-2001047893-A1 NEW AZABICYCLOOCTANE DERIVATIVES USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137766-A1 Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias KCNH1, KCNH2, KCNH3 MAPT 4857/4885USP2 3107/4885CTNNB1 2317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.